
Benzinga Pro data, Kala Pharmaceuticals (NASDAQ:KALA) reported Q4 sales of $1.86 million. Earnings fell to a loss of $47.57 million, resulting in a 69.12% decrease from last quarter. Kala Pharmaceuticals collected $3.07 million in revenue during Q3, but reported earnings showed a $28.13 million loss.